Miikka‐Juhani Honka

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity